INVESTORS Login About Putnam Careers Contact us Products How we invest Retirement College Perspectives Forms Tax center Accounts Home Market updates Equity Insights Investing in the biology revolution Investing in the biology revolution Shep Perkins, CFA Chief Investment Officer, Equities William C. Rives, CFA Portfolio Manager, Analyst Technology has transformed our world — and our investment opportunities — over the past decade. So, what comes next? What will be the next disruptor to bring dramatic change to our everyday lives and great potential to our investment portfolios? In our view, “synbio” is a top candidate. We believe synbio — synthetic biology— could rival trends like e-commerce, cloud computing, and electric vehicles as the next big revolution. From mRNA Covid-19 vaccines to mushroom yoga mats to Impossible Burgers to lab-grown seafood, we’re already seeing tangible signs of the enormous potential in synbio. Today, we all know a lot more about biology Now that we are well into the second year of the Covid-19 pandemic, the importance of biology has become much more obvious. The virus itself and the health care industry’s response, most notably the development of vaccines, have highlighted the power in the process of engineering cells and proteins. Historically esoteric concepts like PCR and mRNA are now part of our daily conversations and no longer the exclusive domain of scientists. Synbio: Biology innovation beyond health care What is less obvious — and very exciting for investors — is the potential for biology outside of health care. Synbio is used to design and grow products of superior quality and, more important, to create products that are significantly more sustainable. Synbio has the potential to replace many of today’s chemical- and petroleum-based manufacturing processes, so it offers compelling environmental benefits. In some cases, synbio involves designing a completely new custom DNA sequence and inserting it into a cell. In other cases, adjustments are made to existing microbes. And since DNA code is just another form of data, we believe it has the potential to benefit from an improvement curve similar to the one that has been demonstrated in computing. While this sounds like science fiction, we’ve had the ability to program cells — a process known as DNA synthesis — for quite a while. Interest in "synbio" is growing rapidly Number of academic citations of synthetic biology Source: National Institutes of Health. One early and fun example of synbio can be found with athletic apparel retailer Lululemon Athletica. The company has partnered with scientists at Bolt Threads to develop innovative and sustainable bags and yoga mats made from the root structure of mushrooms. Lululemon is also experimenting with synbio-derived fabrics. Another example is Impossible Foods, a private company that develops plant-based substitutes for meat products. Its Impossible Burger is made with a protein produced by genetically modified soy grown in bioreactors like the ones that Sartorius, a pharmaceutical and laboratory equipment supplier, sells to its customers to create biological drugs. Other companies are developing biological cement, biological chemicals, and modified row crops that can pull nitrogen out of the air, eliminating the need for applied fertilizer. Over time, we believe synbio could impact nearly every part of the physical goods economy. It can create new and exciting products and solve challenging sustainability problems. The clothing industry, for example, uses hydrocarbons for 60% of its materials. What if synbio company Genomatica can create bio-based nylon? This intersection of technology and biology can be a powerful economic driver for many industries and could become the defining source of innovation and disruption in the coming decades. From mRNA Covid-19 vaccines to mushroom yoga mats to Impossible Burgers to lab-grown seafood, we’re already seeing tangible signs of the enormous potential in synbio. The investment opportunity From an investing standpoint, we see opportunities within three broad categories. Technology enablers. We view these companies as pick-and-shovel providers for synbio. They are companies that sell equipment and materials necessary to analyze, design, and build biological materials such as DNA, RNA, and microbes. For example, Twist Bioscience sells oligos, the building blocks of synthetic DNA. Thermo Fisher Scientific and Danaher sell bioreactors and filtration used to produce biological materials. Synbio companies. These are businesses whose main focus is building biological-based products. These are typically earlier-stage and fast-growth companies like Ginkgo Bioworks, which has created a horizontal platform to help companies design their own bio-products. Another example is Amyris, which produces biologic-based skin care products. We also include traditional biotech companies in this category. Early adopters. These are companies whose core business has not traditionally focused on biology. In our view, these established companies are taking advantage of the potential disruption of synbio. Examples include clothing companies like Lululemon and food companies such as Nomad Foods, which is partnering to offer products like cell-cultured seafood, where cells are extracted from fish in order to reproduce them in a lab setting. We believe synbio will become a major wave of innovation and one of the most exciting areas of the market in the coming years. It could help drive new areas of growth, and many companies can capitalize on this technology. While we are still in the very early innings of this revolution, we believe synbio will grow into a massive market and a potential multi-trillion-dollar opportunity. Holdings in Putnam Research Fund as of 9/30/21: Danaher (0.85% of fund assets); Lululemon Athletica (0.07%); and Thermo Fisher Scientific (0.94%). Amyris, Genomatica, Ginkgo Bioworks, Nomad Foods, Sartorius, and Twist Bioscience were not fund holdings. The views and opinions expressed are those of the authors, are subject to change with market conditions, and are not meant as investment advice. Learn more about Putnam Research Fund. Our investment techniques, analyses, and judgments may not produce the outcome we intend. The investments we select for the fund may not perform as well as other securities that we do not select for the fund. We, or the fund's other service providers, may experience disruptions or operating errors that could have a negative effect on the fund. You can lose money by investing in the fund. Equity leadership team Shep Perkins, CFA Chief Investment Officer, Equities Investing since 1993 Joined Putnam in 2011 Kate Lakin Director of Equity Research Investment industry since 2008 Joined Putnam in 2012 You may also be interested in: The rebound of Chinese tech under "common prosperity" Value investing for all seasons When to pay attention to insider buying For informational purposes only. Not an investment recommendation. This material is provided for limited purposes. It is not intended as an offer or solicitation for the purchase or sale of any financial instrument, or any Putnam product or strategy. References to specific asset classes and financial markets are for illustrative purposes only and are not intended to be, and should not be interpreted as, recommendations or investment advice. The opinions expressed in this article represent the current, good-faith views of the author(s) at the time of publication. The views are provided for informational purposes only and are subject to change. This material does not take into account any investor's particular investment objectives, strategies, tax status, or investment horizon. Investors should consult a financial advisor for advice suited to their individual financial needs. Putnam Investments cannot guarantee the accuracy or completeness of any statements or data contained in the article. Predictions, opinions, and other information contained in this article are subject to change. Any forward-looking statements speak only as of the date they are made, and Putnam assumes no duty to update them. Forward-looking statements are subject to numerous assumptions, risks, and uncertainties. Actual results could differ materially from those anticipated. Past performance is not a guarantee of future results. As with any investment, there is a potential for profit as well as the possibility of loss. Products Insights Research tools Investment strategies Account support About Putnam BY USING THIS SITE, YOU ACKNOWLEDGE AND AGREE TO THE FOLLOWING DISCLAIMER AND TERMS AND CONDITIONS: The third-party information accessible through this site was prepared by, and is the sole responsibility of, independent providers who are not affiliated with Putnam. Putnam has not reviewed the information and does not warrant that the information is accurate, complete, or timely. You further acknowledge and agree that (1) any security mentioned by a third party reflects the independent opinion of the third party, (2) any such third-party data or opinion is provided for your information only, and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation by Putnam, (3) any information you receive may not be considered legal, tax, or investment advice provided by Putnam, and (4) Putnam is not liable for any loss or damages resulting from your use of this information. By clicking on links to third-party sites, or using social media sharing tools, you will leave this Putnam Retail Management hosted property. Putnam Investments is not responsible for the content or services offered on linked websites. Use linked websites at your own risk. Carefully review the site's terms of service and privacy rules as they apply to you. Opinions or recommendations on any linked websites are those of independent providers and do not imply a recommendation from Putnam Investments, which is not responsible for inaccuracies or errors. For informational purposes only. Not an investment recommendation. Shares of mutual funds are not deposits of, or guaranteed or endorsed by, any financial institution; are not insured by the Federal Deposit Insurance Corporation (FDIC), the Federal Reserve Board, or any other agency; and involve risk, including the possible loss of the principal amount invested. The mutual funds, investment products, and services listed on this site generally are not available for sale outside of the United States. The information presented is neither a solicitation nor an offer to sell these products to investors who are not U.S. persons. Privacy, Security, Terms of Use Putnam funds may, at times, invest in the Putnam Cash Collateral Pool, LLC. View more information about this fund. Investment Advisory Services Your financial representative can help you decide which investments suit your goals. Putnam offers mutual funds, separately managed accounts, and model portfolios. Key funds include Putnam Large Cap Value Fund and Putnam Growth Opportunities Fund, as well as Putnam Income Fund. Municipal bond funds that seek tax-free income include Putnam Tax Exempt Income Fund. Check out our Site Map to learn more. Investors should carefully consider the investment objectives, risks, charges, and expenses of a fund before investing. For a prospectus, or a summary prospectus if available, containing this and other information for any Putnam fund or product, contact your financial representative, call Putnam at 1-888-4-PUTNAM (1-888-478-8626), or click on the prospectus section to view or download a prospectus. Please read the prospectus carefully before investing. © 2021 Putnam Retail Management, a member of FINRA and SIPC